Cantor Fitzgerald Upgrades Zevra Therapeutics (NASDAQ:ZVRA) to Strong-Buy
Cantor Fitzgerald upgraded shares of Zevra Therapeutics (NASDAQ:ZVRA – Free Report) to a strong-buy rating in a research note issued to investors on Wednesday,Zacks.com reports. Other equities ...
Fintel on MSN17h
Cantor Fitzgerald Initiates Coverage of Acrivon Therapeutics (ACRV) with Overweight Recommendation
Fintel reports that on January 31, 2025, Cantor Fitzgerald initiated coverage of Acrivon Therapeutics (NasdaqGM:ACRV) with a Overweight recommendation. Analyst Price Forecast Suggests 260.44% Upside ...